Assessment of health-related quality of life (HRQoL) in KEYNOTE-010: A phase 2/3 study of pembrolizumab vs docetaxel in patients with previously treated advanced NSCLC
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2016-10, Vol.27, p.vi422-vi422 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | vi422 |
|---|---|
| container_issue | |
| container_start_page | vi422 |
| container_title | Annals of oncology |
| container_volume | 27 |
| creator | Barlesi, F. Garon, E. Kim, D.-W. Felip, E. Han, J.-Y. Kim, J.-H. Ahn, M.-J.A. Fidler, M.J. Gubens, M.A. Castro, G. Surmont, V. Li, Q. Deitz, A.C. Lubiniecki, G. Herbst, R.S. |
| description | |
| doi_str_mv | 10.1093/annonc/mdw383.19 |
| format | Article |
| fullrecord | <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_annonc_mdw383_19</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0923753419448424</els_id><sourcerecordid>S0923753419448424</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1819-8b95d2793d925c71aebe7d7995ce6ab32fe3fd5d094f923aa617498eeb363ce3</originalsourceid><addsrcrecordid>eNp1kDtPwzAQxy0EEqWwM3qEIa0d5-VuVVUoomoFdGGKHPuiGuWF7aaUL8TXJG1Yme6k0-_-D4RuKRlRwtlYVFVdyXGp9ixhI8rP0ICGEfcSEtBzNCDcZ14csuASXVn7QQiJuM8H6GdqLVhbQuVwneMtiMJtPQOFcKDw504U2h2Ol0LngO8Wry_18h7rCj_P31frzdwjlEzwFDdbYQH7Y4at26kT0UCZmbrQ37tSZLi1WNUSnPiC4sg3wulO1OK9dlvcGGh1vbPFATsDJ22hWlHJblm9zZaza3SRi8LCzd8cos3DfDNbeMv149NsuvQkTWiXNuOh8mPOFPdDGVMBGcQq5jyUEImM-TmwXIWK8CDvGhEionHAE4CMRUwCGyLSv5WmttZAnjZGl8IcUkrSY89p33Pa95xS3iGTHoHOVqvBpFZ2yTrn2oB0qar1__Av6w2Jtw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Assessment of health-related quality of life (HRQoL) in KEYNOTE-010: A phase 2/3 study of pembrolizumab vs docetaxel in patients with previously treated advanced NSCLC</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Barlesi, F. ; Garon, E. ; Kim, D.-W. ; Felip, E. ; Han, J.-Y. ; Kim, J.-H. ; Ahn, M.-J.A. ; Fidler, M.J. ; Gubens, M.A. ; Castro, G. ; Surmont, V. ; Li, Q. ; Deitz, A.C. ; Lubiniecki, G. ; Herbst, R.S.</creator><creatorcontrib>Barlesi, F. ; Garon, E. ; Kim, D.-W. ; Felip, E. ; Han, J.-Y. ; Kim, J.-H. ; Ahn, M.-J.A. ; Fidler, M.J. ; Gubens, M.A. ; Castro, G. ; Surmont, V. ; Li, Q. ; Deitz, A.C. ; Lubiniecki, G. ; Herbst, R.S.</creatorcontrib><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdw383.19</identifier><language>eng</language><publisher>Elsevier Ltd</publisher><ispartof>Annals of oncology, 2016-10, Vol.27, p.vi422-vi422</ispartof><rights>2016 European Society for Medical Oncology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1819-8b95d2793d925c71aebe7d7995ce6ab32fe3fd5d094f923aa617498eeb363ce3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Barlesi, F.</creatorcontrib><creatorcontrib>Garon, E.</creatorcontrib><creatorcontrib>Kim, D.-W.</creatorcontrib><creatorcontrib>Felip, E.</creatorcontrib><creatorcontrib>Han, J.-Y.</creatorcontrib><creatorcontrib>Kim, J.-H.</creatorcontrib><creatorcontrib>Ahn, M.-J.A.</creatorcontrib><creatorcontrib>Fidler, M.J.</creatorcontrib><creatorcontrib>Gubens, M.A.</creatorcontrib><creatorcontrib>Castro, G.</creatorcontrib><creatorcontrib>Surmont, V.</creatorcontrib><creatorcontrib>Li, Q.</creatorcontrib><creatorcontrib>Deitz, A.C.</creatorcontrib><creatorcontrib>Lubiniecki, G.</creatorcontrib><creatorcontrib>Herbst, R.S.</creatorcontrib><title>Assessment of health-related quality of life (HRQoL) in KEYNOTE-010: A phase 2/3 study of pembrolizumab vs docetaxel in patients with previously treated advanced NSCLC</title><title>Annals of oncology</title><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNp1kDtPwzAQxy0EEqWwM3qEIa0d5-VuVVUoomoFdGGKHPuiGuWF7aaUL8TXJG1Yme6k0-_-D4RuKRlRwtlYVFVdyXGp9ixhI8rP0ICGEfcSEtBzNCDcZ14csuASXVn7QQiJuM8H6GdqLVhbQuVwneMtiMJtPQOFcKDw504U2h2Ol0LngO8Wry_18h7rCj_P31frzdwjlEzwFDdbYQH7Y4at26kT0UCZmbrQ37tSZLi1WNUSnPiC4sg3wulO1OK9dlvcGGh1vbPFATsDJ22hWlHJblm9zZaza3SRi8LCzd8cos3DfDNbeMv149NsuvQkTWiXNuOh8mPOFPdDGVMBGcQq5jyUEImM-TmwXIWK8CDvGhEionHAE4CMRUwCGyLSv5WmttZAnjZGl8IcUkrSY89p33Pa95xS3iGTHoHOVqvBpFZ2yTrn2oB0qar1__Av6w2Jtw</recordid><startdate>20161001</startdate><enddate>20161001</enddate><creator>Barlesi, F.</creator><creator>Garon, E.</creator><creator>Kim, D.-W.</creator><creator>Felip, E.</creator><creator>Han, J.-Y.</creator><creator>Kim, J.-H.</creator><creator>Ahn, M.-J.A.</creator><creator>Fidler, M.J.</creator><creator>Gubens, M.A.</creator><creator>Castro, G.</creator><creator>Surmont, V.</creator><creator>Li, Q.</creator><creator>Deitz, A.C.</creator><creator>Lubiniecki, G.</creator><creator>Herbst, R.S.</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20161001</creationdate><title>Assessment of health-related quality of life (HRQoL) in KEYNOTE-010: A phase 2/3 study of pembrolizumab vs docetaxel in patients with previously treated advanced NSCLC</title><author>Barlesi, F. ; Garon, E. ; Kim, D.-W. ; Felip, E. ; Han, J.-Y. ; Kim, J.-H. ; Ahn, M.-J.A. ; Fidler, M.J. ; Gubens, M.A. ; Castro, G. ; Surmont, V. ; Li, Q. ; Deitz, A.C. ; Lubiniecki, G. ; Herbst, R.S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1819-8b95d2793d925c71aebe7d7995ce6ab32fe3fd5d094f923aa617498eeb363ce3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Barlesi, F.</creatorcontrib><creatorcontrib>Garon, E.</creatorcontrib><creatorcontrib>Kim, D.-W.</creatorcontrib><creatorcontrib>Felip, E.</creatorcontrib><creatorcontrib>Han, J.-Y.</creatorcontrib><creatorcontrib>Kim, J.-H.</creatorcontrib><creatorcontrib>Ahn, M.-J.A.</creatorcontrib><creatorcontrib>Fidler, M.J.</creatorcontrib><creatorcontrib>Gubens, M.A.</creatorcontrib><creatorcontrib>Castro, G.</creatorcontrib><creatorcontrib>Surmont, V.</creatorcontrib><creatorcontrib>Li, Q.</creatorcontrib><creatorcontrib>Deitz, A.C.</creatorcontrib><creatorcontrib>Lubiniecki, G.</creatorcontrib><creatorcontrib>Herbst, R.S.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Barlesi, F.</au><au>Garon, E.</au><au>Kim, D.-W.</au><au>Felip, E.</au><au>Han, J.-Y.</au><au>Kim, J.-H.</au><au>Ahn, M.-J.A.</au><au>Fidler, M.J.</au><au>Gubens, M.A.</au><au>Castro, G.</au><au>Surmont, V.</au><au>Li, Q.</au><au>Deitz, A.C.</au><au>Lubiniecki, G.</au><au>Herbst, R.S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Assessment of health-related quality of life (HRQoL) in KEYNOTE-010: A phase 2/3 study of pembrolizumab vs docetaxel in patients with previously treated advanced NSCLC</atitle><jtitle>Annals of oncology</jtitle><date>2016-10-01</date><risdate>2016</risdate><volume>27</volume><spage>vi422</spage><epage>vi422</epage><pages>vi422-vi422</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><pub>Elsevier Ltd</pub><doi>10.1093/annonc/mdw383.19</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2016-10, Vol.27, p.vi422-vi422 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_annonc_mdw383_19 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| title | Assessment of health-related quality of life (HRQoL) in KEYNOTE-010: A phase 2/3 study of pembrolizumab vs docetaxel in patients with previously treated advanced NSCLC |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T03%3A57%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Assessment%20of%20health-related%20quality%20of%20life%20(HRQoL)%20in%20KEYNOTE-010:%20A%20phase%202/3%20study%20of%20pembrolizumab%20vs%20docetaxel%20in%20patients%20with%20previously%20treated%20advanced%20NSCLC&rft.jtitle=Annals%20of%20oncology&rft.au=Barlesi,%20F.&rft.date=2016-10-01&rft.volume=27&rft.spage=vi422&rft.epage=vi422&rft.pages=vi422-vi422&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdw383.19&rft_dat=%3Celsevier_cross%3ES0923753419448424%3C/elsevier_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_els_id=S0923753419448424&rfr_iscdi=true |